Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

OBJECTIVES: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with active psori...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T, Coates, Laura C, McInnes, Iain B, Mease, Philip J, Merola, Joseph F, Tanaka, Yoshiya, Asahina, Akihiko, Gossec, Laure, Gottlieb, Alice B, Warren, Richard B, Ink, Barbara, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Landewé, Robert BM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579478/
https://www.ncbi.nlm.nih.gov/pubmed/37696588
http://dx.doi.org/10.1136/ard-2023-224431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579478/
https://www.ncbi.nlm.nih.gov/pubmed/37696588
http://dx.doi.org/10.1136/ard-2023-224431

Ejemplares similares